Cook Medical named Rob Lyles executive vice president, the latest move in a larger management shift at the Indiana medtech maker.
Lyles was formerly vice president of Cook’s peripheral intervention division. He has been with the company since 2003 and was named division VP in 2007. Lyles’ promotion follows the advancement of Pete Yonkman to president of the Cook Medical. Mark Breedlove, a 19-year veteran of Cook Medical, will succeed Lyles as VP of the peripheral intervention division.
Thermo Fisher Scientific Inc. (NYSE:TMO) has acquired Boulder, Colo.-based picoSpin for an undisclosed amount.
The Waltham, Mass.-based Thermo Fisher will fold picoSpin into its chemical analysis business as part of the Analytical Technologies business unit, according to a prepared release.
MASSDEVICE ON CALL — A look at the top 10 medical device makers found that more than half had little to no environmental initiatives in place.
In a study conducted by Green Research, the companies with stainability initiatives were:
MASSDEVICE ON CALL — As manufacturing costs rise in western nations, BRIC countries like India and China become more alluring for med-tech makers, well-known cardiologist and professor Dr. Balram Bhargava told a Cambridge University lecture.
"There is a thinning medical pipeline in the west," Bhargava said. "Innovation centres are developing in these countries and they will probably develop devices that will ultimately be accepted by the west, be partnered by the west and therefore western companies will move to Indian soil to manufacture."
MASSDEVICE ON CALL — The European Commission in Brussels cleared Thermo Fisher Scientific Inc.’s (NYSE:TMO) $3.5 billion cash buyout of Swedish blood test maker Phadia, finding that "the transaction would not raise competition concerns."
"After investigating the proposed transaction, the Commission determined that the parties are not close competitors and are currently primarily constrained by other competitors, which would continue to constrain the merged entity," according to a press release.
Thermo Fisher Scientific Inc. (NYSE:TMO) closed its highly anticipated $3.6 billion acquisition of Swedish blood test maker Phadia.
The all-cash deal, which is closed yesterday, gives Thermo Fisher expanded reach in specialty diagnostics. Phadia supplies more than 70 percent of the world’s allergy laboratory tests and 40 percent of autoimmunity tests.
Thermo Fisher Scientific Inc. (NYSE:TMO) unveiled that its upcoming offering meant to help fund its $3.5 billion acquisition of Swedish blood test maker Phadia at will be priced at $2.2 billion.
The offering includes notes $1 billion aggregate of 2.25 percent senior notes due 2016 at an issue price of 99.826 percent of the principal amount, and $1.1 billion aggregate of 3.6 percent senior notes due 2021 at an issue price of 99.809 percent of the principal amount.